Naltrexone - Immune Therapeutics

Drug Profile

Naltrexone - Immune Therapeutics

Alternative Names: IRT-103; IRT-104; LDN - Immune Therapeutics; Lodonal; Low-dose naltrexone - Immune Therapeutics

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer GB Pharma Holdings; Immune Therapeutics; Penn State Milton S. Hershey Medical Center
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Immunomodulators; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis; Crohn's disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Autoimmune disorders; Cancer
  • Registered HIV infections
  • Phase II Crohn's disease
  • Clinical Phase Unknown Cervical cancer

Most Recent Events

  • 06 Sep 2017 Naltrexone - Immune Therapeutics market licensed to Omaera Pharmaceuticals in Kenya
  • 31 May 2017 Immune Therapeutics expects to launch Naltrexone for HIV infections, Cancer and Autoimmune disorders in Ivory Coast in 2017
  • 31 May 2017 Immune Therapeutics, GB Pharma Holdings and Rougier Pharma Afrique sign a momeorandum of understanding for distribution of Naltrexone - Immune Therapeutics in Ivory Coast
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top